Dados B3 › COCE5 × CPFE3 · Português
Each row uses the most recent year in which BOTH companies have the figure, and says which year that is. A cell with ! carries a caveat — hover to read it. We do not name a winner: that would be a recommendation, and this site does not give any.
| indicator | COCE5 | CPFE3 | year |
|---|---|---|---|
| ROE | 7.4%! | 25.4% | 2025 |
| ROIC | 12.2% | 16.2% | 2025 |
| ROA | 2.6% | 7.3% | 2025 |
| Gross margin | 19.3% | 31.8% | 2025 |
| EBIT margin | 15.0% | 24.9% | 2025 |
| Net margin | 4.3% | 12.9% | 2025 |
| Net debt/EBITDA | 2.87x | 1.94x | 2025 |
| Current ratio | 0.55x | 0.93x | 2025 |
| Revenue growth (1y) | 8.7% | 4.1% | 2025 |
| Revenue growth (5y CAGR) | 8.9% | 7.5% | 2025 |
| Piotroski F-Score | 5/9 | 6/9 | 2025 |
Priced at the first session on or after the day each filing became public — never the period close.
| indicator | COCE5 | CPFE3 | year |
|---|---|---|---|
| P/E | 6.71x | 9.86x | 2025 |
| P/B | 0.48x | 2.41x | 2025 |
| EV/EBITDA | 4.20x | 5.97x | 2025 |
| FCF yield | -8.7% | 12.5% | 2025 |
Numbers on this page are live. Data version 2026-09-01-supressao-declarada · page generated 2026-09-08 14:39 UTC. If this does not match /saude, you are reading a cached copy.
Home · Methodology · Transparency · Audit it